Guangdong Taienkang Pharmaceutical Co. Ltd

Tyen Kang announced on September 23 that its controlled subsidiary, Jiangsu Bochuangyuan Pharmaceutical Technology Co., Ltd., has recently completed data compilation for the Phase IIa clinical trial of its self-developed Class 1 innovative drug CKBA cream for rosacea. Preliminary analysis results show that 1.50% CKBA cream demonstrated good efficacy and safety in treating moderate to severe papulopustular rosacea. After 16 weeks of treatment, the proportion of subjects whose Investigator's Global Assessment score reached 0 or 1 was 60.00%, or 9 out of 15, and the inflammatory lesion count decreased by 39.06 from baseline, a reduction of 76.40%. No serious adverse events occurred during the trial, nor did any adverse events lead to subject withdrawal, and no new safety risk signals were identified. Only a small number of subjects experienced brief, mild local irritation symptoms, all of which resolved after symptomatic treatment, indicating that CKBA cream is well tolerated.

Tai'en Kang announced on September 21 that its wholly-owned subsidiary Huabo Kaisheng has received the Drug Registration Certificate for Labetalol Hydrochloride Tablets issued by the National Medical Products Administration. The drug is a commonly used alpha and beta receptor blocker, mainly for treating various types of hypertension, and is particularly effective in managing pregnancy-induced hypertension syndrome. Currently, a total of nine companies in China have obtained registration approval for this drug, and Huabo Kaisheng's Labetalol Hydrochloride Tablets are the second domestically produced variety to pass consistency evaluation. In the first half of 2026, Tai'en Kang achieved revenue of 320 million yuan and a net profit attributable to the parent company of 3.72 million yuan.

Tai En Kang's wholly owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. has received a drug clinical trial approval notice issued by the National Medical Products Administration, approving the initiation of clinical trials for cisplatin polymeric micelle for injection as a monotherapy in advanced malignant tumors. The product is registered as a Class 2.2 chemical drug, with acceptance number CXHL2600715. Cisplatin is a platinum-containing anticancer drug that is clinically effective against various solid tumors such as ovarian cancer, prostate cancer, and lung cancer, but it lacks tumor tissue selectivity and has serious side effects including renal impairment and neurotoxicity. The polymeric micelle formulation developed by the company aims to reduce toxic side effects and achieve passive targeting. According to data from Menet, domestic terminal sales of antitumor chemical drugs exceeded 70 billion yuan in 2024. As of the announcement date, no domestic company has obtained a registration certificate for this product. The company cautioned that the drug still needs to complete clinical trials and undergo review and approval before it can be marketed, and there are risks such as progress falling short of expectations and uncertainty regarding approval and launch timing.

Tai En Kang and Procare Cell have signed a strategic cooperation agreement, under which Tai En Kang obtains exclusive commercial promotion service rights in China, including Hong Kong, Macau, and Taiwan, for the ocular surface cell therapy product MSCohi-O lens. The product is a Class 1 therapeutic biological product that uses a silicone hydrogel carrier to enable stable retention of umbilical cord mesenchymal stem cells on the ocular surface. It has received orphan drug designation from the U.S. FDA for chronic ocular graft-versus-host disease and obtained IND clinical trial approval in both China and the United States, and is currently in Phase IIa clinical trials. The agreement stipulates that after Procare Cell submits a marketing authorization application for any indication, the two parties will initiate negotiations for Tai En Kang to serve as the exclusive commercial service provider. The company stated that the agreement is a framework arrangement and is not expected to have a material impact on current operating results, and that drug development involves uncertainties.

Shandong Huabo Kaisheng Biotechnology, a wholly-owned subsidiary of Guangdong Teyankang Pharmaceutical, has had its baricitinib tablets selected in the 12th National Centralized Drug Procurement. The drug specification is 2 mg, 28 tablets per box, indicated for rheumatoid arthritis. The company stated that during the procurement cycle, medical institutions will prioritize the use of selected products. Following the signing and implementation of procurement contracts, this will facilitate volume sales and market expansion, enhance brand influence, and have a positive impact on future operating performance. However, there remains uncertainty regarding subsequent matters such as the signing of procurement agreements and the impact on company performance.

Tai En Kang announced that as of July 31, 2026, the company had repurchased a total of 2.43 million shares, representing 0.4768% of total share capital, with a total repurchase amount of 48.44 million yuan and a repurchase price range of 17.75 yuan to 21.54 yuan per share. In the first quarter of 2026, the company achieved revenue of 190 million yuan and net profit attributable to the parent company of 28.58 million yuan.